Osteoarthritis
Glucosamine and chondroitin combined therapy and monotherapy vs celecoxib and placebo for knee OA
N Engl J Med. 2006 Feb 23;354(8):795-8081583 patients with symptomatic knee osteoarthritis were randomized to either glucosamine monotherapy, chondroitin monotherapy, combined glucosamine and chondroitin therapy, celecoxib 200mg daily, or placebo. Patients were assessed over 24 weeks of treatment. In the primary analysis, only the celecoxib group demonstrated a significantly higher rate of patients attaining the primary efficacy endpoint - a reduction of WOMAC pain by a minimum of 20% relative to baseline - compared to placebo. However, when only analyzing patients with moderate-to-severe pain at baseline, the combined therapy group did demonstrate significant differences compared to placebo in the primary efficacy measure, as well as some secondary outcome measures.
Unlock the full article
Get unlimited access to OrthoEvidence with a free trial
Start TrialCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or continue reading this full article
Register Now
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
